Size : 2mg
Synonyms:
| Description | Tunicamycin is a mixture of antibiotics that inhibit N-linked glycosylation by blocking GlcNAc phosphotransferase (GPT). Tunicamycin has antitumor activity, as well as anti-bacterial, anti-fungal, and anti-viral activity. |
| Targets & IC50 | Phospho-N-acetylmuramyl-pentapeptide transferase (MraY):0.31 µM |
| In vitro | Method: Human hepatocellular carcinoma cells Hep3B were treated with Tunicamycin (1 μg/mL), camptothecin (3 μM), etoposide (5 μM), taxol (0.1 μM), and vincristine (0.1 μM) for 48 h, and cell death was detected by Flow Cytometry. Result: Tunicamycin significantly inhibited apoptosis induced by TOP inhibitors (camptothecin and etoposide) but not by microtubule-targeting drugs (taxol and vincristine). [1] Method: Human hepatocellular carcinoma cells PLC/PRF/5, MHCC-97L and MHCC-97H were treated with Tunicamycin (2.5 μg/mL) for 24 h, and the expression levels of the target proteins were detected by Western Blot. Result: Tunicamycin inhibited the phosphorylation of Akt in the three hepatocellular carcinoma cell lines. [2] |
| In vivo | Method: To investigate the effects on hepatic energy metabolism, Tunicamycin (1 mg/kg) was administered intraperitoneally to C57BL/6 mice as a single injection. Result: Tunicamycin significantly induced hepatic yellow coloration and endoplasmic reticulum stress, and increased serum aspartate aminotransferase and alanine aminotransferase levels.Tunicamycin altered hepatic energy homeostasis by increasing triglyceride accumulation and decreasing glycogen content. [3] Method: To test the antitumor activity in vivo, Tunicamycin (0.25 mg/kg) was administered orally twice a week for four weeks to Balb/c (nu/nu) mice harboring human triple-negative breast carcinoma tumor MDA-MB-231. Result: Within one week of oral administration of Tunicamycin, MDA-MB-231 tumor xenografts were reduced by 65% and there was no systemic and/or organ failure. [4] |
| Molecular Weight | 718.7034 |
| Formula | C30H46N4O16 |
| Cas No. | 11089-65-9 |
| Smiles | CC(C)C\C=C\C(=O)N[C@@H]1C(O[C@H]2OC(CO)[C@@H](O)[C@H](O)C2NC(C)=O)O[C@@H](CC(O)[C@H]2O[C@H](C(O)[C@H]2O)N2C=CC(=O)NC2=O)C(O)[C@H]1O |
| Relative Density. | 1.57g/cm3 |
| Storage | Keep away from moisture Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||
| Solubility Information | DMSO: 14.37 mg/mL (19.99 mM), Sonication is recommended. | ||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2.00 mg/mL (2.78 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | |||||||||||||||||||||
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|
